EKF Diagnostics to Introduce New Low Cost POC Analyzers at Medica

18 Oct 2012
Share
EKF Diagnostics, worldwide manufacturer of point-of-care (POC) diagnostic tools, will be introducing two new low cost POC analyzers at Medica 2012. The EKF stand (Hall 3 C70) will see the European launch of the new Quo-Lab glycated hemoglobin (HbA1c) analyzer for the affordable management of diabetes, as well as a preview of a new strip-based analyzer for highly accurate near patient testing of ketosis – the STAT-Site™ M bHB.

The semi-automated Quo-Lab HbA1c analyzer is CE marked and provides highly accurate, affordable and easy-to-use technology for GP surgeries, diabetes clinics and laboratories. HbA1c monitoring is increasingly used in the detection and management of diabetes and Quo-Lab is designed to meet the needs of economies where resources are limited and where diabetes is an increasingly large public health issue. Requiring minimal training and just 4 µL of venous or finger prick blood, the small and lightweight Quo-Lab delivers lab-accurate results within four minutes.

EKF will also be previewing its first strip-based ketone analyzer, the STAT-Site™ M bHB, which promises to take testing for ketoacidosis out of the laboratory and into the emergency room. ß-Hydroxybutyrate (bHB) is the main ketone produced during ketosis and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis.

The launch of STAT Site™ M bHB follows the recent success of the ß-Hydroxybutyrate (bHB) LiquiColor® Reagent System developed by EKF subsidiary, Stanbio Laboratory. The bHB liquid stable reagent can be used on any open channel analyzer and is used by 13 of the USA’s top 25 diabetes and endocrinology hospitals to provide rapid, objective results.

Quo-Lab and STAT Site™ M bHB will both be demonstrated at Medica 2012 in a series of free mini-seminars on the EKF Diagnostics stand.

Request Info


Company website

EKF Diagnostics